<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476642</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY0000000</org_study_id>
    <nct_id>NCT03476642</nct_id>
  </id_info>
  <brief_title>Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks</brief_title>
  <official_title>A Volunteer Study to Determine the Anatomical Distribution of Injectate, the Extent of Sensory Block, and the Pharmacokinetics of Ropivacaine Following Erector Spinae Plane (ESP) Blocks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to define the extent of dermatomal anesthesia and
      anatomical spread of injectate (as defined by MRI imaging) that is provided by an ESP block
      at the T5 level, using twenty milliliters of 0.5% ropivacaine.

      The secondary objectives include: 1) the measurement of changes in hemodynamic parameters
      associated with the ESP block, 2) the duration of sensory effects provided by ropivacaine
      with or without epinephrine, 3) the venous plasma concentration of ropivacaine associated at
      various time intervals after completion of the ESP block.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized,double blinded, controlled study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of dermatomal sensory loss</measure>
    <time_frame>0 to 360 minutes from the time of the ESP block</time_frame>
    <description>A consultant anesthesiologist blinded to the randomization allocation will perform a sensory assessment for loss of sensation to cold using ethanol on the skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of sensory loss</measure>
    <time_frame>0 to 360 minutes from the time of the ESP block</time_frame>
    <description>A consultant anesthesiologist blinded to the randomization allocation will perform a sensory assessment for loss of sensation to cold using ethanol on the skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anatomical extent of injectate spread using MRI</measure>
    <time_frame>30 and 90 minutes from the time of the ESP block</time_frame>
    <description>The subject will undergo two MRIs to determine the spread of the anesthetic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous plasma concentration of ropivacaine at periodic time intervals</measure>
    <time_frame>These samples will be repeated at 20, 40, 60, 90, 120, and 240 minutes after completion of the injection of active drug.</time_frame>
    <description>3 ml of blood will be obtained from the Intravenous line already placed in the subject prior to performing the block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure at periodic time intervals</measure>
    <time_frame>Up to 360 minutes from the time of the ESP block</time_frame>
    <description>Non- invasive monitoring of blood pressure every 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any adverse effects or side effects related to injection of the medications</measure>
    <time_frame>0-3 days after the block is complete</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG at periodic time intervals</measure>
    <time_frame>Up to 360 minutes from the time of the ESP block</time_frame>
    <description>Recording ECG every 5 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Distribution of Ropivacaine in Erector Spinae Plane Block</condition>
  <arm_group>
    <arm_group_label>Ropivacaine with Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine without Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process</description>
    <arm_group_label>Ropivacaine with Epinephrine</arm_group_label>
    <arm_group_label>Ropivacaine without Epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process</description>
    <arm_group_label>Ropivacaine with Epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18 to 60 inclusive

          -  Weight between 60 and 100 kg inclusive

          -  Height 160 to190 cm inclusive

        Exclusion Criteria:

          -  Pregnant females

          -  Chronic medical condition requiring medication

          -  History of previous major spinal, abdominal or thoracic surgery

          -  Congenital abnormalities of the spine, back, thorax or abdomen

          -  History of major trauma to the thorax or abdomen;

          -  Allergy to ropivacaine or other amide local anesthetics

          -  The presence of any metallic implant in their body

          -  Any contraindication to magnetic resonance imaging as determined by completion of a
             standard questionnaire administered to all patients undergoing magnetic resonance
             imaging.

          -  Allergy to Gadolinium radiological contrast agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjib Adhikary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjib Adhikary, MD</last_name>
    <phone>717-531-6140</phone>
    <email>sadhikary1@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane McCloskey</last_name>
    <phone>717-531-0003</phone>
    <phone_ext>280359</phone_ext>
    <email>dmccloskey@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Pendergrass, BS</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>282465</phone_ext>
      <email>mpendergrass@pennstatehealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sanjib Adhikary, MD</last_name>
      <phone>717-531-6140</phone>
      <email>sadhikary1@pennstatehealth.psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Sanjib Adhikary</investigator_full_name>
    <investigator_title>Associate Professor, Director Acute Pain, Regional Anesthesia/Ortho</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

